Marvell Technology, Inc. current report, 27 August 2021

Marvell Technology, Inc. Form 8-K Summary

Business context and reporting period

Marvell Technology, Inc. filed this Current Report on August 27, 2021, under Item 8.01 in connection with certain registration statements related to its acquisition of Inphi Corporation.

  • Included: Inphi’s unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2021.
  • Included: Unaudited pro forma condensed combined statements of operations for the year ended January 30, 2021, and the six months ended July 31, 2021, reflecting the Inphi acquisition.

Financial metrics and liquidity

The filing text provided does not include revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics. Those details may be contained in Exhibits 99.1 and 99.2, which are referenced but not reproduced in the supplied text.

Material changes versus the prior comparable period

The filing does not present a standalone period-over-period comparison for Marvell. It provides historical Inphi financial statements and pro forma combined operating information intended to illustrate the effect of the acquisition.

Guidance, outlook, risks, contingencies, and unusual items

No management guidance, outlook, risk-factor update, contingency, or unusual operating item is described in the supplied filing text. The principal event is the filing of acquisition-related financial statements and pro forma information in connection with registration statements.

Important facts to verify

  • Review Exhibit 99.1 for Inphi’s reported revenue, operating results, cash flows, assets, liabilities, and equity for the three months ended March 31, 2021.
  • Review Exhibit 99.2 for the pro forma combined operating results, transaction adjustments, and basis of presentation for the periods ended January 30, 2021, and July 31, 2021.
  • Confirm the acquisition accounting, transaction date, consideration transferred, and any material financing or purchase-accounting adjustments.
  • Assess whether the registration statements or related exhibits contain additional risk factors, dilution information, or integration assumptions.